A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS
A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Sponsor: Bosnalijek D.D
Terminated
During the Covid-19 pandemic, the study was unable to enrol further patients.
Other Multiple Sclerosis, Relapsing-Remitting trials with similar outcome
Listed as NCT03283397, this PHASE3 trial focuses on Multiple Sclerosis, Relapsing-Remitting and remains terminated or withdrawn. Sponsored by Bosnalijek D.D, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2023 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — May 2020 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bosnalijek D.D
- MonitorCRO
For direct contact, visit the study record on ClinicalTrials.gov .